150 related articles for article (PubMed ID: 10960842)
41. Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate.
Tamas EF; Epstein JI
Am J Surg Pathol; 2006 Aug; 30(8):980-5. PubMed ID: 16861969
[TBL] [Abstract][Full Text] [Related]
42. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
43. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Colecchia M; Frigo B; Del Boca C; Guardamagna A; Zucchi A; Colloi D; Leopardi O
J Clin Pathol; 1997 May; 50(5):384-8. PubMed ID: 9215120
[TBL] [Abstract][Full Text] [Related]
44. Significance of the Gleason scoring system after neoadjuvant hormonal therapy.
Bentley G; Dey J; Sakr WA; Wood DP; Pontes JE; Grignon DJ
Mol Urol; 2000; 4(3):125-;discussion 131. PubMed ID: 11062366
[TBL] [Abstract][Full Text] [Related]
45. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
[TBL] [Abstract][Full Text] [Related]
46. Prostatic intraepithelial neoplasia and endocrine manipulation.
van der Kwast TH; Labrie F; Têtu B
Eur Urol; 1999; 35(5-6):508-10. PubMed ID: 10325515
[TBL] [Abstract][Full Text] [Related]
47. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
[TBL] [Abstract][Full Text] [Related]
48. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.
Civantos F; Marcial MA; Banks ER; Ho CK; Speights VO; Drew PA; Murphy WM; Soloway MS
Cancer; 1995 Apr; 75(7):1634-41. PubMed ID: 8826921
[TBL] [Abstract][Full Text] [Related]
49. [Histological investigation of prostate cancer treated with hormonal agents].
Azumi M; Saga Y; Hashimoto H; Kakizaki H
Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867
[TBL] [Abstract][Full Text] [Related]
50. Use of immunohistochemistry in routine workup of prostate needle biopsies: a tertiary academic institution experience.
Watson K; Wang C; Yilmaz A; Bismar TA; Trpkov K
Arch Pathol Lab Med; 2013 Apr; 137(4):541-5. PubMed ID: 23273390
[TBL] [Abstract][Full Text] [Related]
51. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
53. The relation of beclin 1 and bcl-2 expressions in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: a tissue microarray study.
Baspinar S; Bircan S; Orhan H; Kapucuoglu N; Bozkurt KK
Pathol Res Pract; 2014 Jul; 210(7):412-8. PubMed ID: 24690321
[TBL] [Abstract][Full Text] [Related]
54. [Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Nagashima T; Niiro M; Hirayama K; Date S; Okihara K; Mukaisho K
Hinyokika Kiyo; 2012 Aug; 58(8):457-60. PubMed ID: 23052274
[TBL] [Abstract][Full Text] [Related]
55. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
Zerbib M; Payan C
Urology; 1996 Oct; 48(4):661-3. PubMed ID: 8886082
[No Abstract] [Full Text] [Related]
56. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells.
Meyer-Siegler K
J Interferon Cytokine Res; 2000 Sep; 20(9):769-78. PubMed ID: 11032396
[TBL] [Abstract][Full Text] [Related]
57. Effects of neoadjuvant androgen deprivation therapy on prostatic cancer.
Polito M; Muzzonigro G; Minardi D; Montironi R
Eur Urol; 1996; 30 Suppl 1():26-31; discussion 38-9. PubMed ID: 8977987
[TBL] [Abstract][Full Text] [Related]
58. Small cell-like change in prostatic intraepithelial neoplasia, intraductal carcinoma, and invasive prostatic carcinoma: a study of 7 cases.
Lee S; Han JS; Chang A; Ross HM; Montironi R; Yorukoglu K; Lane Z; Epstein JI
Hum Pathol; 2013 Mar; 44(3):427-31. PubMed ID: 23026197
[TBL] [Abstract][Full Text] [Related]
59. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma.
Meyer-Siegler KL; Bellino MA; Tannenbaum M
Cancer; 2002 Mar; 94(5):1449-56. PubMed ID: 11920501
[TBL] [Abstract][Full Text] [Related]
60. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
